Evidence map›Paper›PMID 40715048›Full record

ArticleSignal transduction and targeted therapy2025

Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRAS

Ying Yuan, Yanhong Deng, Yongdong Jin, Zengqing Guo, Yueyin Pan, Cunji Wang, Zhiwu Wang, Yi Hu, Dong Hua, Xiangjiao Meng and 17 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07581912 (Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07581912 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases

TypeinterventionalSponsorZhejiang UniversityRan2026 to 2031Enrolled40ConditionsColorectal Cancer, KRAS G12C Mutant Advanced Solid Tumors, Fulzerasib, Cetuximab N01Armsfulzerasib, cetuximab N01
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Systematic and precise interventions for KRAS-mutant cancers.Experimental hematology & oncology · 2026
    Review
  5. Review
  6. Review
  7. Annals of gastroenterology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Ying YuanDepartment of Medical Oncology, Key Laboratory of Cancer Prevention and Intervention, Ministry of Education, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.ORCID 0000-0002-3922-9553
Yanhong DengDepartment of Medical Oncology, The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Yongdong JinDepartment of Medical Oncology, Sichuan Cancer Hospital, Chengdu, China.
Zengqing GuoDepartment of Special Demand Ward/Department of Clinical Nutrition, Fujian Cancer Hospital, Fuzhou, China.
Yueyin PanDepartment of Tumor Chemotherapy, Anhui Provincial Hospital, Hefei, China.
Cunji WangDepartment of Oncology, Hunan Traditional Chinese Medical College No.1 Affiliated Hospital, Zhuzhou, China.
Zhiwu WangThe Second Department of Radiochemotherapy, Tangshan People's Hospital, Tangshan, China.
Yi HuDepartment of Medical Oncology, Chinese PLA General Hospital, Beijing, China.
Dong HuaDepartment of Oncology, Wuxi People's Hospital, Wuxi, China.
Xiangjiao MengThoracic Radiation Oncology Ward IV, Shandong Provincial Cancer Hospital, Jinan, China.
Zhiye ZhangDepartment of Medical Oncology, The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China.
Mingfang ZhaoDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Xiaorong DongDepartment of Thoracic Oncology, Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, China.
Dingzhi HuangDepartment of Pulmonary Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Xiaoyan LiDepartment of Medical Oncology, Beijing Tiantan Hospital of Capital Medical University, Beijing, China.
Lian LiuDepartment of Medical Oncology, Qilu Hospital of Shandong University, Jinan, China.
Meili SunDepartment of Medical Oncology, Central Hospital Affiliated to Shandong First Medical University, Jinan, China.
Huijuan WangDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, China.
Xiuwen WangDepartment of Medical Oncology, Qilu Hospital of Shandong University (Qingdao), Qingdao, China.
Nong YangDepartment of Pulmonary Gastroenterology, The Second People's Hospital of Hunan Province, Changsha, China.
Mingjun ZhangDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.
Sheng HuHepatopancreatobiliary Surgery Department, Hubei Cancer Hospital, Wuhan, China.
Dongde WuHepatopancreatobiliary Surgery Department, Hubei Cancer Hospital, Wuhan, China.
Jingjing HuangInnovent Biologics Co., Ltd., Suzhou, China.
Sujie ZhangInnovent Biologics Co., Ltd., Suzhou, China.
Mengna HuangInnovent Biologics Co., Ltd., Suzhou, China.
Kefeng DingDepartment of Colorectal Surgery and Oncology, Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China. dingkefeng@zju.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IBI351 (also known as fulzerasib or GFH925), an irreversible covalent inhibitor of KRAS

Indexed as

Colorectal NeoplasmsProto-Oncogene Proteins p21(ras)AdultAgedEast Asian PeopleFemaleHumansMaleMiddle AgedMutationNeoplasm MetastasisKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID40715048
PMCPMC12297441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.